Literature DB >> 18304688

Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

Muzaffer Metintas1, Guntulu Ak, Sebnem Parspour, Huseyin Yildirim, Sinan Erginel, Fusun Alatas, Hasan F Batirel, Cumhur Sivrikoz, Selma Metintas, Emine Dundar.   

Abstract

In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. We evaluate the factors affecting LD frequency and discuss the use of PR in MPM patients. Histopathologically diagnosed 212 MPM patients who had not received PR were evaluated in terms of development of LD. Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. The LD frequency was 13.2% for all patients. The median survival rate was 9 or 10 months in patients with or without LD, respectively. A higher LD frequency was observed in patients receiving thoracotomy. The LD appearance time in supportive care is short. The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response. LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low. LD was not associated with the stage of the disease. The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18304688     DOI: 10.1016/j.lungcan.2007.12.022

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

Review 1.  What is the role of radiotherapy in malignant pleural mesothelioma?

Authors:  Allan Price
Journal:  Oncologist       Date:  2011-02-23

2.  Radiotherapy applications of patients with malignant mesothelioma: A single center experience.

Authors:  Muge Akmansu; Ozge Petek Erpolat; Fatih Goksel; Evrim Tunc; Can Ozturk
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-09

Review 3.  Is there a role for prophylactic radiotherapy to intervention tract sites in patients with malignant pleural mesothelioma?

Authors:  Paul Halford; Amelia O Clive
Journal:  Transl Lung Cancer Res       Date:  2018-10

Review 4.  Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.

Authors:  Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-09

Review 5.  Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.

Authors:  Periklis Perikleous; David A Waller
Journal:  J Vis Surg       Date:  2017-06-22

6.  Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.

Authors:  Amelia O Clive; Paula Wilson; Hazel Taylor; Anna J Morley; Emma de Winton; Niki Panakis; Najib Rahman; Justin Pepperell; Timothy Howell; Timothy J P Batchelor; Nikki Jordan; Y C Gary Lee; Lee Dobson; Nick A Maskell
Journal:  BMJ Open       Date:  2015-01-09       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.